Quick Answer
Neuphoria Therapeutics Inc. reported Operating Income of -$1.13 million for fiscal year 2025.
Neuphoria Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$1.13M | +93.7% |
| 2024 | -$17.89M | +18.6% |
| 2023 | -$21.98M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$4.06M | -9.6% | +28.2% |
| September 30, 2025 | -$5.65M | -58.4% | -147.2% |
| March 31, 2025 | $11.98M | +600.3% | +423.4% |
| December 31, 2024 | -$3.70M | +18.7% | -3.8% |
| September 30, 2024 | -$3.57M | +34.7% | -49.0% |
| March 31, 2024 | -$2.39M | — | +47.4% |
| December 31, 2023 | -$4.55M | — | +16.7% |
| September 30, 2023 | -$5.47M | — | — |
- Neuphoria Therapeutics Inc. showed an increase of +93.7% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Neuphoria Therapeutics Inc.’s operating income has grown by 94.9% (from -$21.98 million to -$1.13 million).
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: